Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 269

1.

Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.

Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG.

Br J Haematol. 2005 Oct;131(2):166-71.

PMID:
16197445
2.

Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.

J Clin Oncol. 2007 Mar 20;25(9):1048-53.

PMID:
17369568
3.

The effect of the JAK2 V617F mutation on PRV-1 expression.

Mnjoyan Z, Yoon D, Li J, Delhommeau F, Afshar-Kharghan V.

Haematologica. 2006 Mar;91(3):411-2.

4.

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.

Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland DG.

Cancer. 2006 Feb 1;106(3):631-5.

5.

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D.

Br J Haematol. 2005 Nov;131(3):320-8.

PMID:
16225651
6.

Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.

Tutaeva V, Misurin AV, Michiels JJ, Rozenberg JM, Sokolova MA, Ivanova VL, Kolosheinova TI, Manakova TE, Levina AA, Semenova EA, Khoroshko ND.

Hematology. 2007 Dec;12(6):473-9.

PMID:
17852451
7.

A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.

Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P.

Leukemia. 2006 Jun;20(6):1055-60.

PMID:
16572198
8.

Epigenetic control of PRV-1 expression on neutrophils.

Jelinek J, Li J, Mnjoyan Z, Issa JP, Prchal JT, Afshar-Kharghan V.

Exp Hematol. 2007 Nov;35(11):1677-83.

PMID:
17976520
10.

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Eur J Haematol. 2007 Dec;79(6):508-15.

PMID:
17961178
11.

Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases.

Vannucchi AM, Guglielmelli P, Antonioli E, Mappa S, Pancrazzi A, Bogani C, Ponziani V, Bosi A.

Br J Haematol. 2006 Mar;132(5):652-4; author reply 654. No abstract available.

PMID:
16445842
12.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
13.

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, Vanelli L, Arcaini L, Burcheri S, Malcovati L, Lazzarino M, Cazzola M.

Blood. 2006 May 1;107(9):3676-82.

14.

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.

Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, Boiret-Dupré N, Skoda RC, Hermouet S.

Blood. 2006 Sep 15;108(6):1865-7.

15.
16.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Review.

PMID:
16919893
17.

Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.

Nakatani T, Imamura T, Ishida H, Wakaizumi K, Yamamoto T, Otabe O, Ishigami T, Adachi S, Morimoto A.

Pediatr Blood Cancer. 2008 Dec;51(6):802-5. doi: 10.1002/pbc.21730.

PMID:
18802948
18.

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.

N Engl J Med. 2005 Apr 28;352(17):1779-90.

19.

[New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].

Larsen TS, Pallisgaard N, Christensen JH, Gram-Hansen P, Kerndrup GB, Møller MB, Hasselbalch HC.

Ugeskr Laeger. 2006 Sep 25;168(39):3295-9. Review. Danish.

PMID:
17032591
20.

[Not just another kinase. New knowledge about myeloproliferative disease].

Bjerrum OW.

Ugeskr Laeger. 2006 Sep 25;168(39):3293. Danish. No abstract available.

PMID:
17032590

Supplemental Content

Support Center